stat3-in-3

STAT3-IN-3 is a potent and highly selective targeted STAT3 inhibitor with significant anti-proliferative activity. It effectively induces apoptosis in breast cancer cells. As a mitochondrially targeted STAT3 inhibitor with great research potential, it has good application value in tumor mechanism exploration and anti-cancer research.

STAT3-IN-31 (compound K2071), derived from STATtic, acts as an inhibitor of both STAT3 and mitotic processes. This compound interrupts mitotic progression and impacts the formation of the mitotic spindle. Additionally, STAT3-IN-31 hampers migration in glioblastoma cells, suppresses cellular proliferation within tumor spheroids, induces senescence in glioblastoma, and inhibits the growth of Temozolomide-resistant cells while reducing the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein (MCP-1).

STAT3-IN-34 (Compound 15E) acts as a STAT3 inhibitor, blocking both the nuclear translocation and the transcriptional regulator activity of STAT3. It effectively inhibits HaCaT cell proliferation with an IC50 value of 0.008 μM. Additionally, STAT3-IN-34 reduces IL-17A expression and mitigates Imiquimod-induced psoriasis in mouse models.

STAT3-IN-35 is a STAT3 inhibitor that binds to the SH2 domain. This compound inhibits the phosphorylation of STAT3 and exhibits antiproliferative activity in triple-negative breast cancer (TNBC) cell lines. Additionally, STAT3-IN-35 has demonstrated toxicity and potent antitumor activity in TNBC xenograft models.

STAT3-IN-36 (compound 11g) is a tritarget inhibitor that selectively targets LRPPRC, STAT3, and CDK1, exhibiting potent anticancer activity. This compound binds to LRPPRC, STAT3, and CDK1, demonstrating more effective anticancer effects than those of TMF or Capecitabine. Additionally, STAT3-IN-36 exhibits an IC50 value of 1.8 μM in HGC27 cells.

STAT3-IN-39 (compound 10K) is an orally active inhibitor of STAT3, demonstrating effective inhibition of STAT3 phosphorylation with an IC50 of 0.47 μM in NIH-3T3 cells. It hinders TGF-β1-induced fibrotic responses and prevents epithelial-mesenchymal transition in A549 cells. STAT3-IN-39 is applicable for research related to idiopathic pulmonary fibrosis.

STAT3-IN-38 (Compound 4m) is a STAT3 inhibitor with a dissociation constant (K_D) of 45.33 µM for rhSTAT3, and is a derivative of Celastrol. It binds to the SH2 domain of the STAT3 protein, inhibiting phosphorylation at the pTyr705 site and suppressing downstream gene expression of Survivin and Mcl-1. STAT3-IN-38 can arrest the cell cycle and induce apoptosis in colorectal cancer cells.

STAT3-IN-37 (Compound 101) is an inhibitor of STAT3, with an IC50 of 15 nM as measured by DNA-HTRF assay and 2 nM as determined through human whole blood SOCS3 qPCR assay.

STAT3-IN-33 (compound 7f) is a potent STAT3 inhibitor with anticancer properties. It exhibits antiproliferative activity in HCT116, MCF-7, and MDA-MB-231 cells, with IC50 values of 6.44, 3.29, and 4.86 μM, respectively. STAT3-IN-33 is applicable for breast and colon cancer research.

1. Ginkgetin has anti-influenza virus and anti-fungal activities. 2. Ginkgetin has anti-inflammatory activity, can down-regulates COX-2 induction in vivo against skin inflammatory responses. 3. Ginkgetin is a good STAT3 inhibitor and may be a useful lead

STAT3-IN-B9 (B9) is an inhibitor of abnormal STAT3 activation and inhibits the proliferation of tumor cells including MDA-MB-468, MDA-MB-231, and DU145.

STAT3-IN-1 selective and orally active inhibitor of STAT3(in HT29 and MDA-MB 231 cells, with IC50 values of 1.82 μM and 2.14 μM , respectively), induces tumor apoptosis.

STAT3-D11-PROTAC-VHL (Compound D11-PROTAC) is a PROTAC degrader targeting signal transducer and activator of transcription 3 (STAT3). It demonstrates anti-tumor activity with IC50 values of 1335 nM in HeLa cells and 1973 nM in MCF-7 cells. The compound binds to the DNA binding domain of STAT3, recruits the E3 ligase VHL to form a ternary complex, leading to ubiquitination and subsequent proteasomal degradation of STAT3. Additionally, STAT3-D11-PROTAC-VHL inhibits tumor cell growth, induces cell cycle arrest and apoptosis (apoptosis), and suppresses tumor immune evasion.

STAT3/AKT-IN-1 is a dual inhibitor of the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signaling pathways, demonstrating anti-tumor activity and inducing apoptosis in SGC-7901 cells.

STAT3/NF-κB-IN-1 is a potent inhibitor of STAT3 and NF-κB, exhibiting IC50 values of 5.86 μM for STAT3 and 4.22 μM for NF-κB in 4 T1 cells. It induces apoptosis by upregulating key apoptotic regulators (caspases-3, 9, Bax) and downregulating Bcl-2 expression. STAT3/NF-κB-IN-1 shows significant anticancer activity against breast cancer cell lines and can reduce tumor volume in vivo. It is applicable for research in breast cancer.

STAT3-IN-44 is a potent STAT3 inhibitor with IC50 values of 1.84 μM (C6 cells) and 4.81 μM (A549 cells). It inhibits the phosphorylation of STAT3, downregulates Bcl-2 expression, and upregulates Caspase-3 expression, thereby promoting late-stage apoptosis. STAT3-IN-44 effectively suppresses tumor cell proliferation and migration and is applicable in research on cancers such as glioma and lung cancer.

PDGFRA/CAIX/XII-IN-1 is a multi-target inhibitor targeting PDGFRA, CA IX and CA XII, with an IC50 of 20 nM against PDGFRA and Ki values of 93.3 nM and 80.0 nM against CA IX and CA XII respectively. It targets and binds to the ATP-binding pocket of PDGFRA, thereby blocking the activation of downstream signaling pathways such as STAT3, AKT and ERK1/2. It induces G0/G1 phase cell cycle arrest and initiates endogenous apoptotic procedures, manifested as cleavage and activation of PARP-1, caspase-9 and caspase-3, upregulation of caspase 3/7 activity and inhibition of Mcl-1 protein expression. It exerts significant anti-proliferative effects in eosinophilic leukemia cells and can serve as a candidate tool compound for mechanism and efficacy research of leukemia.

STAT3-IN-46 is a selective, orally active inhibitor of the signal transducer and activator of transcription 3 (STAT3), with a KD value of 323.3 nM. It binds directly to the SH2 domain of STAT3, inhibiting the IL-6/JAK/STAT3 signaling pathway with an IC50 value of 0.87 μM, and decreases levels of c-Myc and Bcl-2. STAT3-IN-46 is applicable in cancer research, including studies on triple-negative breast cancer.

CHI3L1-IN-4 (Compound 8) is an inhibitor of chitinase-3-like protein 1 (CHI3L1), exhibiting a Kd of 6.8 μM. By disrupting the CHI3L1 pathway, CHI3L1-IN-4 significantly reduces the viability of glioblastoma (GBM) spheres and lowers phosphorylated STAT3 levels. This compound is applicable in GBM research.

STAT3-IN-52 (Compound 9) is a selective and orally active inhibitor of signal transducer and activator of transcription 3 (STAT3). It binds to the pY705 site of STAT3 with a Ki of 440 nM, effectively hindering STAT3 phosphorylation and dimerization. STAT3-IN-52 exhibits potent cytotoxicity against various cancer cells, such as breast cancer MDA-MB-231 (IC50 of 0.7 μM), medulloblastoma UW426, and pancreatic cancer BKPC3 cells. The compound induces apoptosis, inhibits STAT3's nuclear translocation and DNA-binding activity, and downregulates the expression of the STAT3 target gene MMP9. STAT3-IN-52 is useful in research related to cancers with aberrant STAT3 activation.

CHI3L1-IN-6 (Compound 9e) is a CHI3L1 inhibitor, exhibiting a Kd value of 19.11 μM against human CHI3L1. This compound can interrupt the interaction between CHI3L1 and Galectin-3 and inhibit the STAT3 signaling pathway. Additionally, CHI3L1-IN-6 demonstrates anticancer activity against glioblastoma.

CHI3L1-IN-7 is a selective inhibitor of CHI3L1, with a Kd of 7.40 μM and an IC50 of 15.4 μM. This compound disrupts the interaction between CHI3L1 and galectin-3, inhibits STAT3 phosphorylation, and reduces the viability of multicellular 3D glioblastoma spheroids. CHI3L1-IN-7 is useful for research involving glioblastoma and CHI3L1-mediated tumor immunoregulation.

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea is a a derivative of the multiple tyrosine kinase inhibitor sorafenib. 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea potently inhibits the phosphorylation of STAT3 by blocking STAT3 phosphorylation and activation, and induces apoptosis in hepatocellular carcinoma cell lines[1].

1. Tectochrysin (Techtochrysine) has antioxidant effect. 2. Tectochrysin is promising inhibitors for the reversal of ABCG2-mediated drug transport. 3. Tectochrysin leads to apoptotic cell death in NSC-LC cells through activation of DR3 and Fas expression via inhibition of STAT3 phosphorylation.